Education
About Us
Working with TipRanks
Follow Us
Theravance Biopharma (TBPH)
:TBPH
TBPH Stock Chart & Stats
Day’s Range― - ―
52-Week Range$7.44 - $11.88
Previous CloseN/A
Volume28.33K
Average Volume (3M)196.88K
Market Cap
$554.51M
Enterprise Value$392.15M
Total Cash (Recent Filing)$130.85M
Total Debt (Recent Filing)$48.16M
Price to Earnings (P/E)―
Beta0.94
Next Earnings
Aug 12, 2025EPS Estimate
0.67Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.27
Shares Outstanding50,001,330
10 Day Avg. Volume168,411
30 Day Avg. Volume196,882
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.71
Enterprise Value/Revenue6.01
Enterprise Value/Gross Profit6.01
Enterprise Value/Ebitda-9.27
Forecast
1Y Price Target
$19.00Price Target Upside71.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Financial HealthTheravance Biopharma's robust financial position with no debt and a strong cash position provides downside support.
Market ExpansionYupelri has been approved for COPD in China, ahead of expectations, potentially boosting market presence and sales.
Strategic PartnershipsTheravance Biopharma's partnership with Viatris in China, where Viatris has a substantial commercial presence, is expected to benefit Yupelri sales.
Bears Say
Market CompetitionCurrently available treatments for neurogenic orthostatic hypotension and multiple systemic atrophy have poor efficacy and safety profiles, highlighting the market's challenges.
Regulatory Approval RisksAmpreloxetine's ability to capture market share is contingent on positive results from the CYPRESS study, introducing an element of uncertainty.
Theravance Biopharma News
TBPH FAQ
What was Theravance Biopharma’s price range in the past 12 months?
Theravance Biopharma lowest stock price was $7.44 and its highest was $11.88 in the past 12 months.
What is Theravance Biopharma’s market cap?
Theravance Biopharma’s market cap is $554.51M.
When is Theravance Biopharma’s upcoming earnings report date?
Theravance Biopharma’s upcoming earnings report date is Aug 12, 2025 which is in 4 days.
How were Theravance Biopharma’s earnings last quarter?
Theravance Biopharma released its earnings results on May 08, 2025. The company reported -$0.27 earnings per share for the quarter, missing the consensus estimate of -$0.206 by -$0.064.
Is Theravance Biopharma overvalued?
According to Wall Street analysts Theravance Biopharma’s price is currently Undervalued.
Does Theravance Biopharma pay dividends?
Theravance Biopharma does not currently pay dividends.
What is Theravance Biopharma’s EPS estimate?
Theravance Biopharma’s EPS estimate is 0.67.
How many shares outstanding does Theravance Biopharma have?
Theravance Biopharma has 50,001,330 shares outstanding.
What happened to Theravance Biopharma’s price movement after its last earnings report?
Theravance Biopharma reported an EPS of -$0.27 in its last earnings report, missing expectations of -$0.206. Following the earnings report the stock price went down -9.293%.
Which hedge fund is a major shareholder of Theravance Biopharma?
Currently, no hedge funds are holding shares in TBPH
Theravance Biopharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$19.00 (71.33% Upside)
$19.00 (71.33% Upside)
Blogger Sentiment
Bearish
TBPH Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 11.4K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
42.78%
12-Months-Change
Fundamentals
Return on Equity
-31.46%
Trailing 12-Months
Asset Growth
-7.47%
Trailing 12-Months
Company Description
Theravance Biopharma
Theravance Biopharma (TBPH) is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule medicines designed to help patients suffering from serious conditions. The company primarily operates in the pharmaceutical sector, with a core emphasis on respiratory diseases, gastrointestinal disorders, and infectious diseases. Theravance Biopharma leverages its proprietary technology platforms to develop innovative therapeutics aimed at addressing unmet medical needs.
TBPH Company Deck
TBPH Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Theravance Biopharma reported strong financial and operational performance, with notable growth in YUPELRI sales and Trelegy milestones. Despite some challenges related to increased operating expenses and pending litigation, the company's overall financial health and strategic advancements position it well for future success.View all TBPH earnings summariesTBPH Stock 12 Month Forecast
Average Price Target
$19.00
▲(71.33% Upside)
Technical Analysis
Ownership Overview
26.21% Insiders
8.35% Mutual Funds
0.06% Other Institutional Investors
55.74% Public Companies and
Individual Investors